Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 11/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 8/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471666 | 1.00 | COMT (0.55) | COMTNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL21388412 | 0.93 | COMT (0.52) | COMTNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL22578251 | 0.90 | POLB (0.52) | COMTNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL21851566 | 0.89 | COMT (0.52) | COMTNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL31119408 | 0.88 | COMT (0.70) | COMTNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL538657 | 0.88 | COMT (0.70) | COMTNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL8471833 | 0.86 | COMT (0.55) | COMTNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL21686097 | 0.85 | COMT (0.64) | COMTNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL21686045 | 0.84 | COMT (0.68) | COMTNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL15019301 | 0.84 | COMT (0.79) | COMTNPC1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3421456-A1 | NEW ROUTE OF SYNTHESIS FOR OPICAPONE | AZAD Pharmaceutical Ingredients AG (CH) | 2019-01-02 | — | — | EP | claimed |
| US-20180370958-A1 | Route Of Synthesis For Opicapone | AZAD PHARMACEUTICAL INGREDIENTS AG (CH) | 2018-12-27 | — | — | US | claimed |
| US-9446012-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-09-20 | — | — | US | claimed |
| EP-2027091-B1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL PORTELA & CA SA (PT) | 2016-01-06 | — | — | EP | claimed |
| US-8536203-B2 | Pharmaceutical compounds | BIAL-PORTELA & CA, S.A. (PT) | 2013-09-17 | — | — | US | claimed |
| EP-2617713-A1 | New Pharmaceutical Compounds | BIAL - Portela & Ca., S.A. (PT) | 2013-07-24 | — | — | EP | claimed |
| US-20240300930-A1 | NOVEL PROCESS FOR THE PREPARATION OF 2,5-DICHLORO-3-(5-(3,4-DIHYDROXY-5-NITROPHENYL)-1,2,4-OXADIAZOL-3-YL)-4,6-DIMETHYLPYRIDINE-1-OXIDE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2024-09-12 | — | — | US | disclosed |
| WO-2024136689-A1 | PROCESSES AND INTERMEDIATES FOR SYNTHESISING OPICAPONE | BIAL - PORTELA & CA, S.A. (PT) | 2024-06-27 | — | — | WO | disclosed |
| EP-3604299-B1 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-0-METHYL TRANSFERASE INHIBITOR | BIAL PORTELA & CA SA (PT) | 2023-07-26 | — | — | EP | disclosed |
| EP-3604299-B1 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-0-METHYL TRANSFERASE INHIBITOR | BIAL PORTELA & CA SA (PT) | 2023-07-26 | — | — | EP | disclosed |
| EP-3604299-A1 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-0-METHYL TRANSFERASE INHIBITOR | Bial-Portela & CA, S.A. (PT) | 2020-02-05 | — | — | EP | disclosed |
| EP-3604299-A1 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-0-METHYL TRANSFERASE INHIBITOR | Bial-Portela & CA, S.A. (PT) | 2020-02-05 | — | — | EP | disclosed |
| EP-2791134-B1 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-O-METHYLTRANSFERASE INHIBITOR | BIAL PORTELA & Cª S A (PT) | 2019-09-25 | — | — | EP | disclosed |
| US-8536203-B2 | Pharmaceutical compounds | BIAL-PORTELA & CA, S.A. (PT) | 2013-09-17 | — | — | US | disclosed |
| EP-2617713-A1 | New Pharmaceutical Compounds | BIAL - Portela & Ca., S.A. (PT) | 2013-07-24 | — | — | EP | disclosed |
| WO-2013089573-A1 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-O-METHYLTRANSFERASE INHIBITOR | BIAL - PORTELA & Cª., S.A. (PT) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013089573-A1 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-O-METHYLTRANSFERASE INHIBITOR | BIAL - PORTELA & Cª., S.A. (PT) | 2013-06-20 | — | — | WO | disclosed |
| US-20100168113-A1 | Pharmaceutical Compounds | BIAL-PORTELA & CA., S.A. (PT) | 2010-07-01 | — | — | US | disclosed |
| EP-2027091-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - Portela & Ca., S.A. (PT) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007117165-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300930-A1 | NOVEL PROCESS FOR THE PREPARATION OF 2,5-DICHLORO-3-(5-(3,4-DIHYDROXY-5-NITROPHENYL)-1,2,4-OXADIAZOL-3-YL)-4,6-DIMETHYLPYRIDINE-1-OXIDE | NOX4, DDT, QDPR | COMT 160/4885NPC1 3171/4885HPGD 108/4885 |
| US-20100168113-A1 | Pharmaceutical Compounds | PMP22, CNR2, OPRL1 | COMT 10/4885NPC1 90/4885HPGD 307/4885 |
| US-20180370958-A1 | Route Of Synthesis For Opicapone | OPRM1, OPRK1, OPRD1 | COMT 399/4885NPC1 1029/4885HPGD 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.